Validation of the acutely presenting older patient screener for short term mortality prediction in older patients hospitalized for COVID-19

验证急性期老年患者筛查工具在预测新冠肺炎住院老年患者短期死亡率方面的有效性

阅读:1

Abstract

PURPOSE: The aim of this study was to validate the acutely presenting older patient (APOP) screener, routinely used on the Emergency Department to predict risk of adverse outcomes in older people, for prediction of in-hospital mortality and 30-days-mortality in older patients hospitalized for COVID-19. METHODS: Patients ≥ 70 years from a multicenter cohort hospitalized for COVID-19 with measured APOP risk were included. External validation analysis of the APOP screener for in-hospital mortality and 30-days-mortality was performed including discrimination and calibration. RESULTS: 389 patients (median age 80 (IQR 75-85) years, 41.4% female, 138 APOP high risk) were included. APOP high risk patients more often lived institutionalized, (26% vs. 4%; p < 0.001), had more comorbidities (Charlson Comorbidity Index 2 (1-3) vs. 2 (0-3); p = 0.002) and were less often fit (Clinical Frailty Scale 1-3 17% vs. 62%; p < 0.001). 84 patients died in hospital and 114 within 30 days. APOP high risk patients had a higher risk of in-hospital-death [OR 1.6 (95% CI 1.0-2.6)] and death within 30 days [OR 2.7 (95% CI 1.7-4.2)]. The APOP screener discriminated poorly for in-hospital mortality [AUC 0.56 (95% CI 0.48-0.63)] and for 30-days-mortality [AUC 0.62 (95% CI 0.55-0.68)]. Calibration plots revealed overestimation of the screener for both mortality risks. CONCLUSION: The APOP screener had a poor predictive performance for in-hospital mortality and 30-days-mortality in older people hospitalized for COVID-19. Screening tools routinely used on the ED may not be useful to predict mortality in different than usual clinical circumstances such as during a pandemic of a novel disease.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。